COMP <GO>
ABBV vs MRK // GROSS PROFIT MARGIN
AbbVie Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: ABBV 8
— MRK 6
▲ GROSS PROFIT MARGIN LEADER: MRK
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
gross-margins
70.20%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABBV VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABBV | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 70.20% | 74.80% | -4.60 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.00% | 20.70% | +8.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.3x | 15.3x | +18.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.47% | 3.42% | +0.05 | ABBV | /fcf-yield <GO> |
| Operating Margin | 24.60% | 34.30% | -9.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | 6.90% | 28.10% | -21.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 1.30% | +7.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 2.26% | +0.01 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.33 | 5.19 | +0.14 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.60% | +0.80 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.8 | 56.9 | +15.92 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.92 | +0.23 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 113.1x | 18.4x | +94.70 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $513.86B | $361.02B | $152.84B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABBV REV | MRK REV | ABBV GROSS % | MRK GROSS % | ABBV FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.16B | $65.01B | 70.2% | 74.8% | $17.82B | $12.36B |
| FY 2024 | $56.33B | $64.17B | 70.0% | 76.3% | $17.83B | $18.10B |
| FY 2023 | $54.32B | $60.12B | 44.0% | 44.0% | $20.39B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABBV // BETA 1.15
MRK // BETA 0.92